Ovarian and Endometrial Cancer Case-Control Study in Poland
This population-based case-control study of ovarian and endometrial cancer was conducted among female residents of Warsaw and Lodz (Poland) between 2001 and 2003. Investigators in DCEG identified all women with histologically-confirmed ovarian and endometrial carcinoma through a rapid ascertainment system in participating hospitals and cancer registries. The collection of biological specimens included blood, urine, and paraffin-embedded tumor tissue. Control women were randomly selected from complete population lists and were frequency matched to cases on age and study site. A personal interview and blood/mouthwash sample was collected. A total of 347 women with invasive ovarian cancer and 555 women with endometrial cancer were enrolled. Researchers share 2,798 controls between breast, ovarian, and endometrial cancer cases. Researchers constructed tissue microarrays including tumor samples from approximately 200 ovarian cancer cases and 300 endometrial cancer cases for immunohistochemical analyses. Nucleic acids were extracted from tissue cores to create a resource for DNA-based studies.
Investigators are conducting the following:
- Analyses of questionnaire-based factors and anthropometric/physical activity measurements in relation to cancer risk and clinical outcomes;
- Identifying genetic susceptibility markers of cancer risk and clinical outcomes using candidate gene and genome-wide association (GWAS) approaches;
- Analyses of tissue/tumor markers to evaluate relationships with cancer risk factors (known or suspected), and their impact on predicting recurrence and survival after diagnosis;
- Analyses of biomarkers in DNA (somatic changes), cryopreserved blood cells, serum/plasma, and urine in relationship to cancer risk and clinical outcomes.
Current projects include methylation profiling, tumor gene sequencing, microsatellite instability analysis, and immunohistochemistry to study the etiologic heterogeneity of endometrial and ovarian cancers.
For more information, contact Nicolas Wentzensen.